

Rochelle P Walensky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6604389/publications.pdf>

Version: 2024-02-01

295
papers

14,941
citations

16437

64
h-index

26591

107
g-index

301
all docs

301
docs citations

301
times ranked

15721
citing authors

#	ARTICLE	IF	CITATIONS
1	The Survival Benefits of AIDS Treatment in the United States. <i>Journal of Infectious Diseases</i> , 2006, 194, 11-19.	1.9	576
2	Expanded Screening for HIV in the United States – An Analysis of Cost-Effectiveness. <i>New England Journal of Medicine</i> , 2005, 352, 586-595.	13.9	504
3	Cost-effectiveness of Total Knee Arthroplasty in the United States. <i>Archives of Internal Medicine</i> , 2009, 169, 1113.	4.3	476
4	Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. <i>JAMA Network Open</i> , 2020, 3, e2016818.	2.8	425
5	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
6	The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States. <i>Medical Care</i> , 2006, 44, 990-997.	1.1	388
7	Risk of Progression to Active Tuberculosis Following Reinfection With <i>Mycobacterium tuberculosis</i> . <i>Clinical Infectious Diseases</i> , 2012, 54, 784-791.	2.9	303
8	Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2015, 67, 203-215.	1.5	279
9	Cost-Effectiveness of HIV Treatment in Resource-Poor Settings – The Case of Côte d'Ivoire. <i>New England Journal of Medicine</i> , 2006, 355, 1141-1153.	13.9	253
10	HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. <i>Clinical Infectious Diseases</i> , 2009, 48, 806-815.	2.9	240
11	Risk of meticillin resistant <i>Staphylococcus aureus</i> and <i>Clostridium difficile</i> in patients with a documented penicillin allergy: population based matched cohort study. <i>BMJ: British Medical Journal</i> , 2018, 361, k2400.	2.4	223
12	Impact of Obesity and Knee Osteoarthritis on Morbidity and Mortality in Older Americans. <i>Annals of Internal Medicine</i> , 2011, 154, 217.	2.0	201
13	Scientific consensus on the COVID-19 pandemic: we need to act now. <i>Lancet, The</i> , 2020, 396, e71-e72.	6.3	189
14	Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. <i>Annals of Internal Medicine</i> , 2006, 145, 797.	2.0	183
15	Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-Effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1316-1323.	2.9	177
16	Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016. <i>JAMA Internal Medicine</i> , 2019, 179, 1376.	2.6	173
17	Review of Human Immunodeficiency Virus Type 1-Related Opportunistic Infections in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2003, 36, 652-662.	2.9	171
18	The “ART” of Linkage: Pre-Treatment Loss to Care after HIV Diagnosis at Two PEPFAR Sites in Durban, South Africa. <i>PLoS ONE</i> , 2010, 5, e9538.	1.1	171

#	ARTICLE	IF	CITATIONS
19	Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2009, 49, 1570-1578.	2.9	167
20	Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. <i>BMC Medicine</i> , 2011, 9, 59.	2.3	158
21	From Mitigation to Containment of the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1889.	3.8	147
22	Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. <i>Health Affairs</i> , 2021, 40, 42-52.	2.5	147
23	Loss to Care and Death Before Antiretroviral Therapy in Durban, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 135-139.	0.9	143
24	Intensive Tuberculosis Screening for HIV-Infected Patients Starting Antiretroviral Therapy in Durban, South Africa. <i>Clinical Infectious Diseases</i> , 2010, 51, 823-829.	2.9	142
25	Visual Screening for Malignant Melanoma. <i>Archives of Dermatology</i> , 2007, 143, 21-8.	1.7	130
26	The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. <i>Aids</i> , 2008, 22, 2025-2033.	1.0	130
27	Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. <i>New England Journal of Medicine</i> , 2013, 369, 1715-1725.	13.9	122
28	Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 154-161.e6.	1.5	122
29	Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. <i>Annals of Internal Medicine</i> , 2013, 158, 84.	2.0	117
30	When to Start Antiretroviral Therapy in Resource-Limited Settings. <i>Annals of Internal Medicine</i> , 2009, 151, 157.	2.0	113
31	Who starts antiretroviral therapy in Durban, South Africa? not everyone who should. <i>Aids</i> , 2010, 24, S37-S44.	1.0	110
32	HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.	3.8	109
33	Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. <i>American Journal of Medicine</i> , 2005, 118, 292-300.	0.6	108
34	Cost-Effectiveness of HIV Testing and Treatment in the United States. <i>Clinical Infectious Diseases</i> , 2007, 45, S248-S254.	2.9	108
35	Barriers to care among people living with HIV in South Africa: Contrasts between patient and healthcare provider perspectives. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 843-853.	0.6	108
36	Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfecting populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7042-7047.	3.3	107

#	ARTICLE	IF	CITATIONS
37	Effectiveness of Pediatric Antiretroviral Therapy in Resource-limited Settings: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2009, 49, 1915-1927.	2.9	107
38	All-Cause Excess Mortality and COVID-19-Related Mortality Among US Adults Aged 25-44 Years, March-July 2020. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 785.	3.8	101
39	Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. <i>Clinical Infectious Diseases</i> , 2010, 51, 392-400.	2.9	100
40	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1613.	2.6	99
41	Integrating Social Contact and Environmental Data in Evaluating Tuberculosis Transmission in a South African Township. <i>Journal of Infectious Diseases</i> , 2014, 210, 597-603.	1.9	98
42	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. <i>American Journal of Medicine</i> , 2003, 115, 632-641.	0.6	97
43	The Lifetime Medical Cost Savings From Preventing HIV in the United States. <i>Medical Care</i> , 2015, 53, 293-301.	1.1	94
44	Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2010, 5, e13132.	1.1	93
45	Natural history of colonization with methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and vancomycin-resistant <i>Enterococcus</i> (VRE): a systematic review. <i>BMC Infectious Diseases</i> , 2014, 14, 177.	1.3	93
46	Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1672-1681.	1.9	93
47	Routine Voluntary HIV Testing in Durban, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 181-186.	0.9	87
48	The Cost of Penicillin Allergy Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1019-1027.e2.	2.0	87
49	The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. <i>Clinical Infectious Diseases</i> , 2012, 54, 1504-1513.	2.9	85
50	Revising Expectations from Rapid HIV Tests in the Emergency Department. <i>Annals of Internal Medicine</i> , 2008, 149, 153.	2.0	79
51	Emergency Provider Attitudes and Barriers to Universal HIV Testing in the Emergency Department. <i>Journal of Emergency Medicine</i> , 2012, 42, 7-14.	0.3	79
52	Improving Clinical Outcomes in Patients With Methicillin-Sensitive <i>Staphylococcus aureus</i> Bacteremia and Reported Penicillin Allergy. <i>Clinical Infectious Diseases</i> , 2015, 61, 741-749.	2.9	79
53	HIV type-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. <i>Antiviral Therapy</i> , 2009, 14, 523-531.	0.6	79
54	Managing the Demand for Global Health Education. <i>PLoS Medicine</i> , 2011, 8, e1001118.	3.9	78

#	ARTICLE	IF	CITATIONS
55	Effective HIV Case Identification Through Routine HIV Screening at Urgent Care Centers in Massachusetts. <i>American Journal of Public Health</i> , 2005, 95, 71-73.	1.5	77
56	Newer drugs and earlier treatment. <i>Aids</i> , 2012, 26, 45-56.	1.0	74
57	Two Drugs or Three? Balancing Efficacy, Toxicity, and Resistance in Postexposure Prophylaxis for Occupational Exposure to HIV. <i>Clinical Infectious Diseases</i> , 2004, 39, 395-401.	2.9	72
58	Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in CÔte d'Ivoire: a trial-based analysis. <i>Aids</i> , 2005, 19, 1299-1308.	1.0	72
59	Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000382.	3.9	70
60	The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy. <i>Aids</i> , 2012, 26, 987-995.	1.0	70
61	The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive <i>Staphylococcus aureus</i> Bacteremia. <i>PLoS ONE</i> , 2016, 11, e0159406.	1.1	70
62	Rapid HIV Testing at Home: Does It Solve a Problem or Create One?. <i>Annals of Internal Medicine</i> , 2006, 145, 459.	2.0	69
63	Identifying Undiagnosed Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2002, 162, 887.	4.3	66
64	Assessing the Impact of Federal HIV Prevention Spending on HIV Testing and Awareness. <i>American Journal of Public Health</i> , 2006, 96, 1038-1043.	1.5	66
65	Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A CÔte d'Ivoire Appraisal. <i>PLoS Medicine</i> , 2009, 6, e1000173.	3.9	66
66	Linkage to HIV, TB and Non-Communicable Disease Care from a Mobile Testing Unit in Cape Town, South Africa. <i>PLoS ONE</i> , 2013, 8, e80017.	1.1	66
67	Risk Factors for Late-Stage HIV Disease Presentation at Initial HIV Diagnosis in Durban, South Africa. <i>PLoS ONE</i> , 2013, 8, e55305.	1.1	64
68	Filtration Efficiency, Effectiveness, and Availability of N95 Face Masks for COVID-19 Prevention. <i>JAMA Internal Medicine</i> , 2020, 180, 1612.	2.6	63
69	Refusing HIV Testing in an Urgent Care Setting: Results from the "Think HIV" Program. <i>AIDS Patient Care and STDs</i> , 2006, 20, 84-92.	1.1	62
70	Integrating HIV Screening into Routine Health Care in Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2010, 50, S77-S84.	2.9	60
71	Anaphylaxis after rechallenge with abacavir. <i>Aids</i> , 1999, 13, 999.	1.0	59
72	Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. <i>Journal of Infectious Diseases</i> , 2008, 197, 1324-1332.	1.9	58

#	ARTICLE	IF	CITATIONS
73	Depressive Symptoms and Their Impact on Health-seeking Behaviors in Newly-diagnosed HIV-infected Patients in Durban, South Africa. <i>AIDS and Behavior</i> , 2012, 16, 2226-2235.	1.4	57
74	Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?. <i>Osteoarthritis and Cartilage</i> , 2013, 21, 655-667.	0.6	56
75	Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 258-268.	0.9	55
76	The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 26-35.	0.9	55
77	Cost-Effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India. <i>Clinical Infectious Diseases</i> , 2010, 50, 416-425.	2.9	54
78	US medical specialty global health training and the global burden of disease. <i>Journal of Global Health</i> , 2013, 3, 020406.	1.2	54
79	What Will It Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001156.	3.9	53
80	Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency. <i>Journal of Infectious Diseases</i> , 2016, 214, 1319-1328.	1.9	52
81	The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 784-791.	2.9	50
82	HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. <i>Antiviral Therapy</i> , 2009, 14, 523-31.	0.6	50
83	Counselor- Versus Provider-Based HIV Screening in the Emergency Department: Results From the Universal Screening for HIV Infection in the Emergency Room (USHER) Randomized Controlled Trial. <i>Annals of Emergency Medicine</i> , 2011, 58, S126-S132.e4.	0.3	49
84	The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men. <i>Clinical Infectious Diseases</i> , 2007, 44, 1115-1122.	2.9	48
85	Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. <i>Aids</i> , 2007, 21, S117-S128.	1.0	48
86	The Impact of The President's Emergency Plan for AIDS Relief (PEPFAR) beyond HIV and Why It Remains Essential. <i>Clinical Infectious Diseases</i> , 2010, 50, 272-275.	2.9	48
87	The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001725.	3.9	48
88	Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2017, 65, 1266-1271.	2.9	48
89	Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential. <i>Annals of Internal Medicine</i> , 2019, 170, 614.	2.0	48
90	Projecting the Benefits of Antiretroviral Therapy for HIV Prevention: The Impact of Population Mobility and Linkage to Care. <i>Journal of Infectious Diseases</i> , 2012, 206, 543-551.	1.9	47

#	ARTICLE	IF	CITATIONS
91	Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. <i>Clinical Infectious Diseases</i> , 2013, 56, 430-446.	2.9	47
92	Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 154-160.	0.9	46
93	Recorded Penicillin Allergy and Risk of Mortality: a Population-Based Matched Cohort Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 1685-1687.	1.3	46
94	Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. <i>PLoS ONE</i> , 2014, 9, e85197.	1.1	45
95	Quantification of Shared Air: A Social and Environmental Determinant of Airborne Disease Transmission. <i>PLoS ONE</i> , 2014, 9, e106622.	1.1	45
96	The impact of active mentorship: results from a survey of faculty in the Department of Medicine at Massachusetts General Hospital. <i>BMC Medical Education</i> , 2018, 18, 108.	1.0	45
97	HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 310-316.	0.9	43
98	The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review. <i>BMC Public Health</i> , 2017, 17, 954.	1.2	43
99	Loss to Follow-Up and Mortality Among HIV-Infected People Co-Infected With TB at ART Initiation in Durban, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 25-30.	0.9	42
100	Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 432-438.	0.9	42
101	WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. <i>PLoS ONE</i> , 2011, 6, e20224.	1.1	41
102	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	2.9	41
103	Discontinuation of Contact Precautions for Methicillin-Resistant <i>Staphylococcus aureus</i> : A Randomized Controlled Trial Comparing Passive and Active Screening With Culture and Polymerase Chain Reaction. <i>Clinical Infectious Diseases</i> , 2013, 57, 176-184.	2.9	40
104	Comparative Pricing of Branded Tenofovir Alafenamide vs Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate vs Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 172, 583-590.	2.0	40
105	Screening for acute HIV infection in South Africa: finding acute and chronic disease*. <i>HIV Medicine</i> , 2011, 12, 46-53.	1.0	39
106	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1523-1531.	1.9	39
107	Home testing for HIV infection in resource-limited settings. <i>Current HIV/AIDS Reports</i> , 2009, 6, 217-223.	1.1	37
108	Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed hiv-infected adults: a prospective, clinic-based study. <i>BMC Infectious Diseases</i> , 2014, 14, 110.	1.3	37

#	ARTICLE	IF	CITATIONS
109	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. <i>Annals of Internal Medicine</i> , 2022, 175, 479-489.	2.0	37
110	Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1288-1294.e1.	1.5	36
111	The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. <i>Annals of Internal Medicine</i> , 2016, 165, 325.	2.0	36
112	Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. <i>Lancet HIV</i> , 2019, 6, e182-e190.	2.1	36
113	Serosurveillance and the COVID-19 Epidemic in the US. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 749.	3.8	36
114	Routine HIV Testing in Adolescents and Young Adults Presenting to an Outpatient Clinic in Durban, South Africa. <i>PLoS ONE</i> , 2012, 7, e45507.	1.1	36
115	Factors Associated with Refusal of Rapid HIV Testing in an Emergency Department. <i>AIDS and Behavior</i> , 2011, 15, 734-742.	1.4	35
116	Apparent declining efficacy in randomized trials. <i>Aids</i> , 2012, 26, 123-126.	1.0	35
117	Treatment for Primary HIV Infection: Projecting Outcomes of Immediate, Interrupted, or Delayed Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 27-37.	0.9	34
118	HIV Self-testing and the Missing Linkage. <i>PLoS Medicine</i> , 2011, 8, e1001101.	3.9	34
119	Cost-Effectiveness of Laboratory Monitoring in Sub-Saharan Africa: A Review of the Current Literature. <i>Clinical Infectious Diseases</i> , 2010, 51, 85-92.	2.9	33
120	Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. <i>Aids</i> , 2015, 29, 1247-1259.	1.0	33
121	Finding HIV in Hard to Reach Populations: Mobile HIV Testing and Geospatial Mapping in Umlazi Township, Durban, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 1888-1895.	1.4	33
122	Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 69-77.	0.9	32
123	The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 90-97.	1.6	32
124	The Survival Benefits of Antiretroviral Therapy in South Africa. <i>Journal of Infectious Diseases</i> , 2014, 209, 491-499.	1.9	32
125	Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. <i>The Lancet Global Health</i> , 2019, 7, e200-e208.	2.9	32
126	Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2013, 8, e84173.	1.1	32

#	ARTICLE	IF	CITATIONS
127	Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. <i>American Journal of Medicine</i> , 2001, 111, 192-194.	0.6	30
128	The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. <i>Journal of Viral Hepatitis</i> , 2011, 18, 506-512.	1.0	30
129	The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2017, 14, e1002446.	3.9	30
130	Association Between Penicillin Allergy Documentation and Antibiotic Use. <i>JAMA Internal Medicine</i> , 2020, 180, 1120.	2.6	30
131	Investigation of Primary Human Immunodeficiency Virus Infection in Patients Who Test Positive for Heterophile Antibody. <i>Clinical Infectious Diseases</i> , 2001, 33, 570-572.	2.9	29
132	Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. <i>Medical Decision Making</i> , 2005, 25, 321-329.	1.2	29
133	Penicillin Allergy Evaluation Access: A National Survey. <i>Clinical Infectious Diseases</i> , 2020, 71, 2972-2975.	2.9	29
134	Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection. <i>PLoS ONE</i> , 2013, 8, e83389.	1.1	29
135	Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. <i>Aids</i> , 2008, 22, 2359-2369.	1.0	28
136	Insurance coverage and financing landscape for HIV treatment and prevention in the USA. <i>Lancet</i> , The, 2021, 397, 1127-1138.	6.3	28
137	Does Modality of Survey Administration Impact Data Quality: Audio Computer Assisted Self Interview (ACASI) Versus Self-Administered Pen and Paper?. <i>PLoS ONE</i> , 2010, 5, e8728.	1.1	28
138	Home HIV Testing: Good News but Not a Game Changer. <i>Annals of Internal Medicine</i> , 2012, 157, 744.	2.0	27
139	HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. <i>Aids</i> , 2007, 21, 973-982.	1.0	26
140	The Cost-Effectiveness of Tuberculosis Preventive Therapy for HIV-Infected Individuals in Southern India: A Trial-Based Analysis. <i>PLoS ONE</i> , 2012, 7, e36001.	1.1	26
141	The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-Infected Patients in South Africa. <i>Clinical Infectious Diseases</i> , 2013, 56, 587-597.	2.9	26
142	Potential Savings by Reduced CD4 Monitoring in Stable Patients With HIV Receiving Antiretroviral Therapy. <i>JAMA Internal Medicine</i> , 2013, 173, 1746-8.	2.6	26
143	HIV Antiretroviral Therapy Costs in the United States, 2012-2018. <i>JAMA Internal Medicine</i> , 2020, 180, 601.	2.6	26
144	Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. <i>South African Medical Journal</i> , 2008, 98, 204-8.	0.2	26

#	ARTICLE	IF	CITATIONS
145	Genotype assays and third-line ART in resource-limited settings. <i>Aids</i> , 2012, 26, 1083-1093.	1.0	25
146	Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India. <i>PLoS ONE</i> , 2013, 8, e64604.	1.1	25
147	Modeling and Cost-Effectiveness in HIV Prevention. <i>Current HIV/AIDS Reports</i> , 2016, 13, 64-75.	1.1	25
148	Rethinking the Ban "The U.S. Blood Supply and Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2017, 376, 174-177.	13.9	25
149	Where Were the Women? Gender Parity in Clinical Trials. <i>New England Journal of Medicine</i> , 2019, 381, 2491-2493.	13.9	25
150	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018, 21, e25096.	1.2	24
151	Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 1353-1363.	2.9	24
152	Call to action: how can the US Ending the HIV Epidemic initiative succeed?. <i>Lancet, The</i> , 2021, 397, 1151-1156.	6.3	24
153	Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. <i>Value in Health</i> , 2010, 13, 893-902.	0.1	23
154	Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. <i>HIV Medicine</i> , 2011, 12, 97-108.	1.0	23
155	Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations. <i>Annals of Internal Medicine</i> , 2017, 167, 77.	2.0	23
156	Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?. <i>Clinical Infectious Diseases</i> , 2017, 65, 1274-1281.	2.9	23
157	The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. <i>Journal of Adolescent Health</i> , 2018, 62, 22-28.	1.2	23
158	High-cost, high-need patients: the impact of reported penicillin allergy. <i>American Journal of Managed Care</i> , 2020, 26, 154-161.	0.8	23
159	Case 39-2006. <i>New England Journal of Medicine</i> , 2006, 355, 2678-2689.	13.9	22
160	A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial. <i>BMC Infectious Diseases</i> , 2013, 13, 390.	1.3	22
161	Factors Associated with Self-Reported Repeat HIV Testing after a Negative Result in Durban, South Africa. <i>PLoS ONE</i> , 2013, 8, e62362.	1.1	22
162	The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu058.	0.4	22

#	ARTICLE	IF	CITATIONS
163	An electronic surveillance tool for catheter-associated urinary tract infection in intensive care units. <i>American Journal of Infection Control</i> , 2015, 43, 592-599.	1.1	22
164	The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. <i>Journal of Infectious Diseases</i> , 2017, 216, 798-807.	1.9	22
165	First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. <i>Aids</i> , 2011, 25, 479-492.	1.0	21
166	Clinic-Based Routine Voluntary HIV Testing in a Refugee Settlement in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 409-413.	0.9	21
167	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. <i>PLoS ONE</i> , 2014, 9, e113031.	1.1	21
168	A therapeutic HIV vaccine: how good is good enough?. <i>Vaccine</i> , 2004, 22, 4044-4053.	1.7	20
169	Scope of Global Health Training in U.S. Obstetrics and Gynecology Residency Programs. <i>Obstetrics and Gynecology</i> , 2013, 122, 1101-1109.	1.2	20
170	Development, Calibration and Performance of an HIV Transmission Model Incorporating Natural History and Behavioral Patterns: Application in South Africa. <i>PLoS ONE</i> , 2014, 9, e98272.	1.1	20
171	Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial. <i>BMC Infectious Diseases</i> , 2016, 16, 501.	1.3	20
172	The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. <i>Clinical Infectious Diseases</i> , 2020, 70, 633-642.	2.9	20
173	Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. <i>Journal of the International AIDS Society</i> , 2016, 19, 20623.	1.2	19
174	The Epi-TAF for Tenofovir Disoproxil Fumarate?: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 915-918.	2.9	19
175	Respiratory Symptom Incidence among People Using Electronic Cigarettes, Combustible Tobacco, or Both. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 231-234.	2.5	19
176	Estimating Shortages in Capacity to Deliver Continuous Kidney Replacement Therapy During the COVID-19 Pandemic in the United States. <i>American Journal of Kidney Diseases</i> , 2020, 76, 696-709.e1.	2.1	19
177	Resource Burden Associated with Contact Precautions for Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> : The Patient Access Managers' Perspective. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 849-852.	1.0	18
178	High Frequency of Hypothalamic-Pituitary-Adrenal Axis Dysfunction After Local Corticosteroid Injection in HIV-Infected Patients on Protease Inhibitor Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 602-608.	0.9	18
179	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. <i>Annals of Internal Medicine</i> , 2017, 167, 618.	2.0	18
180	The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. <i>HIV Medicine</i> , 2007, 8, 439-450.	1.0	17

#	ARTICLE	IF	CITATIONS
181	Could Early Antiretroviral Therapy Entail More Risks than Benefits in Sub-Saharan African HIV-Infected Adults? A Model-Based Analysis. <i>Antiviral Therapy</i> , 2013, 18, 45-55.	0.6	17
182	Global Health Training in US Graduate Psychiatric Education. <i>Academic Psychiatry</i> , 2014, 38, 426-432.	0.4	17
183	The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. <i>Journal of the International AIDS Society</i> , 2018, 21, e25085.	1.2	17
184	AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus Infection Health Care in the United States. <i>Clinical Infectious Diseases</i> , 2002, 35, 606-610.	2.9	16
185	Implementing a Routine, Voluntary HIV Testing Program in a Massachusetts County Prison. <i>Journal of Urban Health</i> , 2006, 83, 1127-1131.	1.8	16
186	Patient Satisfaction With Rapid HIV Testing in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2011, 58, S49-S52.	0.3	16
187	National Survey of Infection Preventionists: Policies for Discontinuation of Contact Precautions for Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 1272-1275.	1.0	16
188	Concordance of PCR and Culture from Nasal Swabs for Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> in a Setting of Concurrent Antistaphylococcal Antibiotics. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1235-1237.	1.8	16
189	The Challenges Ahead With Monoclonal Antibodies. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2151.	3.8	15
190	Clinical, Laboratory, and Radiologic Characteristics of Patients With Initial False-Negative Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Test Results. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa559.	0.4	15
191	Optimizing Resource Allocation in United States AIDS Drug Assistance Programs. <i>Clinical Infectious Diseases</i> , 2006, 43, 1357-1364.	2.9	14
192	Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection*. <i>HIV Medicine</i> , 2008, 9, 863-7.	1.0	14
193	Rapid HIV testing program implementation: lessons from the emergency department. <i>International Journal of Emergency Medicine</i> , 2009, 2, 187-194.	0.6	14
194	Challenges in Evaluating the Cost-effectiveness of New Diagnostic Tests for HIV-Associated Tuberculosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1021-1026.	2.9	14
195	Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. <i>AIDS Research and Therapy</i> , 2014, 11, 29.	0.7	14
196	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. <i>Clinical Infectious Diseases</i> , 2016, 62, 1454-1462.	2.9	14
197	Cardiovascular risk factors among ART-experienced people with HIV in South Africa. <i>Journal of the International AIDS Society</i> , 2019, 22, e25274.	1.2	14
198	Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 148-156.	0.9	14

#	ARTICLE	IF	CITATIONS
199	Cost-effectiveness Analysis and HIV Screening: The Emergency Medicine Perspective. <i>Annals of Emergency Medicine</i> , 2011, 58, S145-S150.	0.3	13
200	Acceptability of Fingerstick Versus Oral Fluid Rapid HIV Testing. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 588-592.	0.9	13
201	Relationship Between Upper Respiratory Tract Influenza Test Result and Clinical Outcomes Among Critically Ill Influenza Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw023.	0.4	13
202	Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis. <i>JAMA Network Open</i> , 2020, 3, e202739.	2.8	13
203	Acceptability of Fingerstick vs. Oral Fluid Rapid HIV Testing. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, , 1.	0.9	13
204	A Case Series of 59 Patients with Nocardiosis. <i>Infectious Diseases in Clinical Practice</i> , 2001, 10, 249-254.	0.1	12
205	Testing for HIV infection in the United States. <i>Current Infectious Disease Reports</i> , 2007, 9, 76-82.	1.3	12
206	HIV/AIDS: AIDS Drug Assistance Programs in the Era of Routine HIV Testing. <i>Clinical Infectious Diseases</i> , 2008, 47, 695-701.	2.9	12
207	Frequent HIV testing among participants of a routine HIV testing program. <i>Virulence</i> , 2010, 1, 68-71.	1.8	12
208	Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department. <i>PLoS ONE</i> , 2011, 6, e25575.	1.1	12
209	Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. <i>Aids</i> , 2012, 26, 625-634.	1.0	12
210	The Acceptability and Feasibility of Routine Pediatric HIV Testing in an Outpatient Clinic in Durban, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1348-1353.	1.1	12
211	The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	12
212	Assessment of Job Satisfaction and Feeling Valued in Academic Medicine. <i>JAMA Internal Medicine</i> , 2019, 179, 992.	2.6	12
213	Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, S12-S21.	0.9	12
214	Point-of-Care CD4 Testing to Inform Selection of Antiretroviral Medications in South African Antenatal Clinics: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2015, 10, e0117751.	1.1	12
215	Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2009, 17, 130-4.	2.9	12
216	Effectiveness of Antiretroviral Therapy after Protease Inhibitor Failure: An Analytic Overview. <i>Clinical Infectious Diseases</i> , 2004, 38, 1613-1622.	2.9	11

#	ARTICLE	IF	CITATIONS
217	Implications and impact of the new US centers for disease control and prevention HIV testing guidelines. <i>Current Infectious Disease Reports</i> , 2008, 10, 157-163.	1.3	11
218	Cost-Effectiveness of HIV Testing Referral Strategies among Tuberculosis Patients in India. <i>PLoS ONE</i> , 2010, 5, e12747.	1.1	11
219	Estimation of the Prevalence of Undiagnosed and Diagnosed HIV in an Urban Emergency Department. <i>PLoS ONE</i> , 2011, 6, e27701.	1.1	11
220	Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 152-161.	0.9	11
221	Predictors of HIV infection: a prospective HIV screening study in a Ugandan refugee settlement. <i>BMC Infectious Diseases</i> , 2016, 16, 695.	1.3	11
222	The Impact of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) and Vancomycin-Resistant Enterococcus (VRE) Flags on Hospital Operations. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 782-790.	1.0	11
223	Diet, physical activity, and obesity among ART-experienced people with HIV in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 71-77.	0.6	11
224	Expanding provider-initiated HIV testing at STI clinics in China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1316-1319.	0.6	10
225	Feasibility and acceptability of home-based HIV testing among refugees: a pilot study in Nakivale refugee settlement in southwestern Uganda. <i>BMC Infectious Diseases</i> , 2018, 18, 332.	1.3	10
226	New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP). <i>JAMA Network Open</i> , 2019, 2, e195042.	2.8	10
227	Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 344-355.	2.4	10
228	Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. <i>PLoS ONE</i> , 2019, 14, e0225104.	1.1	10
229	Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2077-e2085.	2.9	10
230	Optimizing Treatment for HIV-Infected South African Women Exposed to Single-Dose Nevirapine: Balancing Efficacy and Cost. <i>Clinical Infectious Diseases</i> , 2006, 42, 1772-1780.	2.9	9
231	Improving Outcomes in State AIDS Drug Assistance Programs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 513-521.	0.9	9
232	Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa. <i>Journal of the International AIDS Society</i> , 2019, 22, e25326.	1.2	9
233	The Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella Vaccination to Prevent Measles Importations Among International Travelers From the United States. <i>Clinical Infectious Diseases</i> , 2019, 69, 306-315.	2.9	9
234	CD4 ⁺ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials. <i>Antiviral Therapy</i> , 2010, 15, 351-361.	0.6	8

#	ARTICLE	IF	CITATIONS
235	Impact of rapid screening for discontinuation of methicillin-resistant <i>Staphylococcus aureus</i> contact precautions. <i>American Journal of Infection Control</i> , 2016, 44, 215-221.	1.1	8
236	A Discrete Event Simulation Model of Patient Flow in a General Hospital Incorporating Infection Control Policy for Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA) and Vancomycin-Resistant <i>Enterococcus</i> (VRE). <i>Medical Decision Making</i> , 2018, 38, 246-261.	1.2	8
237	Coronavirus Disease 2019 (COVID-19) Diagnostic Clinical Decision Support: A Pre-Post Implementation Study of CORAL (COvid Risk cALculator). <i>Clinical Infectious Diseases</i> , 2021, 73, 2248-2256.	2.9	8
238	Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. <i>Antiviral Therapy</i> , 2005, 10, 41-52.	0.6	8
239	Monitoring of antiretroviral therapy in low-resource settings. <i>Lancet, The</i> , 2008, 372, 288.	6.3	7
240	Late diagnosis of HIV infection at two academic medical centers: 1994â€“2004. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2008, 20, 977-983.	0.6	7
241	Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. <i>Journal of General Internal Medicine</i> , 2011, 26, 661-667.	1.3	7
242	Combination HIV Prevention: The Value and Interpretation of Mathematical Models. <i>Current HIV/AIDS Reports</i> , 2013, 10, 195-198.	1.1	7
243	Individualizing the WHO HIV and infant feeding guidelines. <i>Aids</i> , 2014, 28, S287-S299.	1.0	7
244	Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 294-302.	0.9	7
245	The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations. <i>Aids</i> , 2017, 31, 2135-2145.	1.0	7
246	The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should Care. <i>Journal of Infectious Diseases</i> , 2019, 221, 690-696.	1.9	7
247	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e1927-e1935.	2.9	7
248	Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. <i>BMJ Open</i> , 2020, 10, e032579.	0.8	7
249	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	7
250	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. <i>HIV Clinical Trials</i> , 2014, 15, 185-198.	2.0	6
251	Housestaff Knowledge Related to Urinary Catheter Use and Catheter-Associated Urinary Tract Infections. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1355-1357.	1.0	6
252	Focusing National Institutes of Health HIV/AIDS Research for Maximum Population Impact. <i>Clinical Infectious Diseases</i> , 2015, 60, 937-940.	2.9	6

#	ARTICLE	IF	CITATIONS
253	Investing in People Who Inject Drugs: A PrEPonderance of Opportunities. <i>Annals of Internal Medicine</i> , 2016, 165, 63.	2.0	6
254	Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies. <i>Medical Decision Making</i> , 2018, 38, 189-199.	1.2	6
255	Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers. <i>JAMA Pediatrics</i> , 2020, 174, e194515.	3.3	6
256	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. <i>MDM Policy and Practice</i> , 2020, 5, 238146832093289.	0.5	6
257	Drug-Resistant Tuberculosis among HIV-Infected Patients Starting Antiretroviral Therapy in Durban, South Africa. <i>PLoS ONE</i> , 2012, 7, e43281.	1.1	5
258	Cost-Effectiveness of Generic Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 776.	2.0	5
259	Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx081.	0.4	5
260	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219068.	1.1	5
261	A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. <i>Journal of Biomedical Informatics</i> , 2020, 107, 103475.	2.5	5
262	Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. <i>AIDS and Behavior</i> , 2021, 25, 2973-2984.	1.4	5
263	The Association Between Symptoms and COVID-19 Test Results Among Healthcare Workers. <i>Annals of Surgery</i> , 2020, 272, e329-e332.	2.1	5
264	Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. <i>HIV Clinical Trials</i> , 2015, 16, 207-218.	2.0	4
265	HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing?. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy170.	0.4	4
266	Comparative Pricing of Branded Tenofovir Alafenamide vs Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate vs Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 173, 507-508.	2.0	4
267	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. , 2017, , 91-111.		4
268	Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. <i>New England Journal of Medicine</i> , 2014, 370, 581-582.	13.9	3
269	HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. <i>International Journal of STD and AIDS</i> , 2015, 26, 704-709.	0.5	3
270	Editorial Commentary: Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1196-1198.	2.9	3

#	ARTICLE	IF	CITATIONS
271	Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis. <i>Annals of the American Thoracic Society</i> , 2020, 17, 202-211.	1.5	3
272	A cohort study to assess a communication intervention to improve linkage to HIV care in Nakivale Refugee Settlement, Uganda. <i>Global Public Health</i> , 2021, 16, 1848-1855.	1.0	3
273	Missed Opportunities: Refusal to Confirm Reactive Rapid HIV Tests in the Emergency Department. <i>PLoS ONE</i> , 2013, 8, e53408.	1.1	3
274	Prevalence and Correlates of Clinically Significant Depressive Symptoms in an Urban Hospital Emergency Department. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	3
275	Adolescent Linkage to Care After a Large-scale Transfer From a Hospital-based HIV Clinic to the Public Sector in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 311-313.	1.1	2
276	Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 486-497.	0.5	2
277	Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz276.	0.4	2
278	Outcomes from an infectious disease physician-guided evaluation of hospitalized persons under investigation for coronavirus disease 2019 (COVID-19) at a large US academic medical center. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 344-347.	1.0	2
279	Addressing Antibiotic Overuse in the Outpatient Setting: Lessons From Behavioral Economics. <i>Mayo Clinic Proceedings</i> , 2021, 96, 537-542.	1.4	2
280	An HIV-Infected Man with an Upset Stomach. <i>Clinical Infectious Diseases</i> , 2008, 47, 979-980.	2.9	1
281	An HIV-Infected Man with an Upset Stomach: (Answer on pages 979-80). <i>Clinical Infectious Diseases</i> , 2008, 47, 935-936.	2.9	1
282	What Is a Modest Public Health Impact?. <i>Archives of Internal Medicine</i> , 2012, 172, 521.	4.3	1
283	The outcome and impact of 10 years of HAART. , 2008, , 45-62.		1
284	Disclosure. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1676.	3.8	0
285	Decreased Progression To Active Tuberculosis Following Re-Infection With M. Tuberculosis. , 2011, , .		0
286	Reply to "Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial". <i>Aids</i> , 2012, 26, 2262-2263.	1.0	0
287	Misinterpretation of HIV Preexposure Prophylaxis Findings. <i>Clinical Infectious Diseases</i> , 2014, 59, 139-141.	2.9	0
288	In Reply. <i>Obstetrics and Gynecology</i> , 2014, 123, 666-667.	1.2	0

#	ARTICLE	IF	CITATIONS
289	The Blood Supply and Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2017, 376, 1486-1487.	13.9	0
290	Reply to Spellberg, Fuchs, and Manian. <i>Clinical Infectious Diseases</i> , 2017, 65, 1599-1599.	2.9	0
291	Further Limitations of a Model-Based Study of People Living With HIV and Lung Cancer Mortality—Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 294.	2.6	0
292	2769. The Clinical and Economic Impact of MMR Vaccinations to Prevent Measles Importations from US Pediatric Travelers Returning from Abroad. <i>Open Forum Infectious Diseases</i> , 2019, 6, S976-S977.	0.4	0
293	Evaluating Point-of-Care Nucleic Acid Tests in Adult Human Immunodeficiency Virus Diagnostic Strategies: A Côte d'Ivoire Modeling Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab225.	0.4	0
294	Impact of Expanded HIV Screening. <i>Annals of Internal Medicine</i> , 2007, 147, 146.	2.0	0
295	OUP accepted manuscript. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, , .	0.6	0